Jiangxi Breast Center Third Hospital of Nanchang, Nanchang, 33009, China.
Mol Biol Rep. 2014 Jan;41(1):19-24. doi: 10.1007/s11033-013-2811-0. Epub 2013 Nov 21.
The objective of this study is to compare the expression level of MAP3K1 between normal mammary gland cells and breast cancer cells, and to analyze the effects of silencing MAP3K1 on breast cancer cells with paclitaxel treatment. Western blotting analysis was used to detect the expression level of MAP3K1 in MCF-7 and MCF-12F cells. The effect of gene silencing through different siRNAs was determined by realtime-PCR. MTT assay was used to test the cell proliferation. Cell cycle was detected by flow cytometry. MAP3K1 protein expression level in breast cancer cells was higher than that in normal mammary gland cells. MAP3K1 siRNA transfection significantly reduced the expression level of MAP3K1, and enhanced paclitaxel-induced cell proliferation inhibition and cell cycle arrest in breast cancer cells. Targeting MAP3K1 expression through small RNA interference can promote the therapeutic effects of paclitaxel in breast cancer.
本研究旨在比较正常乳腺细胞和乳腺癌细胞中 MAP3K1 的表达水平，并分析沉默 MAP3K1 对紫杉醇处理的乳腺癌细胞的影响。通过 Western blot 分析检测 MCF-7 和 MCF-12F 细胞中 MAP3K1 的表达水平。通过实时 PCR 确定不同 siRNA 对基因沉默的影响。MTT 试验检测细胞增殖。通过流式细胞术检测细胞周期。乳腺癌细胞中 MAP3K1 蛋白表达水平高于正常乳腺细胞。MAP3K1 siRNA 转染显著降低 MAP3K1 的表达水平，并增强紫杉醇诱导的乳腺癌细胞增殖抑制和细胞周期阻滞。通过小 RNA 干扰靶向 MAP3K1 表达可增强紫杉醇治疗乳腺癌的疗效。
